biz.yahoo.com/e/130705/ttnp8-k.html
5-Jul-2013
Entry into a Material Definitive Agreement, Financial Statements and Ex
Item 1.01. Entry Into a Definitive Material Agreement.
Amendment to License Agreement
On July 2, 2013, Titan Pharmaceuticals, Inc. (the "Company") and Braeburn Pharmaceuticals Sprl ("Braeburn") entered into a second amendment (the "Amendment") to the License Agreement dated December 14, 2012, as amended (the "Agreement") primarily to establish and provide the parameters for a committee comprised of representatives of Titan and Braeburn responsible for and with the authority to make all decisions regarding the development and implementation of a strategic plan to seek approval from the U.S. Food and Drug Administration ("FDA") of Probuphine� for subdermal use in the maintenance treatment of adult patients with opioid dependence, including development of the strategy for all written and oral communications with the FDA. The Amendment also makes Braeburn the primary contact for FDA communications regarding the Probuphine New Drug Application.
A copy of the Amendment is attached hereto as Exhibit 10.1 and the description thereof contained in this Current Report on Form 8-K is qualified in its entirety be reference to such exhibit.